Literature DB >> 17211644

[Palliative and supportive treatment options in patients with advanced prostate cancer].

T Maurer1, M Retz, J E Gschwend.   

Abstract

In patients with advanced prostate cancer, quality of life and prevention of complications come to the fore. Besides handling local complications such as obstruction, hematuria and lymphedema, treatment of bone metastases and their complications is of great importance. Analgesic measures, bisphosphonates, radiation therapy, radionuclide therapy and neurosurgical procedures are available. Spinal cord compression with acute motor and sensory deficiency requires immediate neurosurgical and/or radiation therapy. Tumor anemia should be treated appropriately.

Entities:  

Mesh：

Year:  2007        PMID： 17211644     DOI： 10.1007/s00120-006-1271-8

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  46 in total

1.  Intravenous bisphosphonates and osteonecrosis.

Authors:  Martin S Greenberg
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2004-09

Review 2.  Current role of lasers in the treatment of benign prostatic hyperplasia (BPH).

Authors:  Rainer M Kuntz
Journal:  Eur Urol       Date:  2006-03-31       Impact factor: 20.096

3.  [Plasma-deposited carbon coating on urological indwelling catheters: Preventing formation of encrustations and consecutive complications].

Authors:  N Laube; J Bradenahl; A Meissner; J V Rappard; L Kleinen; S C Müller
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

4.  Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.

Authors:  Cesar A Migliorati; Mark M Schubert; Douglas E Peterson; Luis Marcelo Seneda
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

5.  Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression.

Authors:  Dirk Rades; Lukas J A Stalpers; Theo Veninga; Rainer Schulte; Peter J Hoskin; Nermina Obralic; Amira Bajrovic; Volker Rudat; Rudolf Schwarz; Maarten C Hulshof; Philip Poortmans; Steven E Schild
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

6.  Indications for percutaneous nephrostomy in patients with obstructive uropathy due to malignant urogenital neoplasias.

Authors:  Frederico R Romero; Marcos Broglio; Silvio R Pires; Roberto F Roca; Ione A Guibu; Marjo D Perez
Journal:  Int Braz J Urol       Date:  2005 Mar-Apr       Impact factor: 1.541

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer.

Authors:  Donald S Crain; Christopher L Amling; Christopher J Kane
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

9.  A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

Authors:  David P Dearnaley; Matthew R Sydes; Malcolm D Mason; Mark Stott; Christopher S Powell; Anne C R Robinson; Peter M Thompson; Leslie E Moffat; Sharon L Naylor; Mahesh K B Parmar
Journal:  J Natl Cancer Inst       Date:  2003-09-03       Impact factor: 13.506

10.  Outcome of transurethral prostatectomy for the palliative management of lower urinary tract symptoms in men with prostate cancer.

Authors:  Vincent J Gnanapragasam; Vinod Kumar; David Langton; Robert S Pickard; Hing Y Leung
Journal:  Int J Urol       Date:  2006-06       Impact factor: 3.369
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.